Underneath the phrases of the settlement, Zydus will manufacture and provide the product, whereas Torrent Pharma has acquired semi-exclusive rights to co-market the product in India beneath its personal model identify Sembolic, leveraging its robust presence in continual therapies and intensive subject power throughout the nation, the Gujarat-based drugmaker stated in a press release.
As a part of the settlement, Torrent Pharma can pay an upfront licensing charge to Zydus, it added.
Zydus has developed an revolutionary formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered utilizing a reusable pen machine.
Semaglutide is indicated for the therapy of adults with insufficiently managed sort 2 diabetes mellitus. It’s also indicated for continual weight administration in adults.
